SCHEMBL2675748

SCHEMBL2675748

O=C(O)c1c(CN2CCN(CCN3CCCC3)CC2)n(-c2ccc(Cl)cc2)c(=O)c2ccccc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP14 P54578 4/20 0.45
MEN1 O00255 2/20 0.44
ALDH1A1 P00352 2/20 0.44
KMT2A Q03164 2/20 0.44
HSD17B10 Q99714 2/20 0.44
NPSR1 Q6W5P4 2/20 0.44
KDM4E B2RXH2 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
GAA P10253 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
HPGD P15428 1/20 0.44
TSHR P16473 1/20 0.44
MAPK1 P28482 1/20 0.44
CYP2C19 P33261 1/20 0.44
HTR7 P34969 4/20 0.44
ABCB1 P08183 2/20 0.42
HTR1A P08908 2/20 0.41
DRD2 P14416 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2677415 0.99 USP14 (0.47) USP14MEN1ALDH1A1KMT2AHSD17B10
SCHEMBL2677561 0.92 ALDH1A1 (0.42) MEN1ALDH1A1KMT2AHSD17B10NPSR1
SCHEMBL2675909 0.92 ABCB1 (0.52) MEN1ALDH1A1KMT2ANPSR1CYP3A4
SCHEMBL2675784 0.91 ALDH1A1 (0.44) MEN1ALDH1A1KMT2AHSD17B10NPSR1
SCHEMBL2676047 0.90 HTR1A (0.48) KMT2AGAATSHRMAPK1HTR7
SCHEMBL2677649 0.90 HTR7 (0.45) MEN1KMT2AHTR7ABCB1ACHE
SCHEMBL2676559 0.89 MEN1 (0.53) MEN1ALDH1A1KMT2AHSD17B10NPSR1
SCHEMBL2676939 0.89 HTR1A (0.47) KMT2AGAAMAPK1HTR7HTR1A
SCHEMBL2676889 0.88 DRD4 (0.51) MEN1ALDH1A1KMT2AKDM4EGAA
SCHEMBL2675842 0.88 HRH3 (0.43) MEN1ALDH1A1KMT2AHSD17B10NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173639-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-05-08 US claimed
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2009-06-04 US claimed
US-8173639-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-05-08 US disclosed
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS KCNQ3, KCNK3, GRIK3 USP14 4363/4885MEN1 3960/4885ALDH1A1 2304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.